Cancer Research Institute

2015 is the inaugural Cancer Research Institute Ride to Conquer Cancer sponsored by Bristol-Myers Squibb.

Funds raised through The Ride will enable the Cancer Research Institute to support life-saving immunotherapy research, treatment and education programs at the top universities and hospitals New York City and around the world.

Cancer Research Institute (CRI), is headquartered in New York City and is the world's only nonprofit organization dedicated exclusively to harnessing the immune system's power to conquer all cancers. Over the past six decades, CRI-funded work has led to a promising new class of cancer treatments today called cancer immunotherapy. These treatments mobilize, strengthen, and sustain the immune system's natural ability to destroy cancer cells, wherever they are in the body.

CRI believes the most intractable cancers will become manageable and non-life threatening in the very near future as a result of scientific advances in immunotherapy. Funds raised by Riders will be allocated immediately by CRI to ensure the sustainability of life-saving immunotherapy programs now underway by world-leading scientists, researchers and doctors in New York City and around the world. Specific programs include:

Research - CRI scientists have played and continue to play a central role in researching and developing today’s most promising immunotherapies. Funds raised enable the continuity of programs to identify new cancer vaccines, advance checkpoint blockade therapy and adoptive cell therapy using genetically engineered T cells.

Treatment - “Checkpoint Blockade Therapy” Funds raised by Riders will support a cutting-edge immunotherapy treatment that uses antibodies to “take the brakes off” immune cells, freeing them to seek out and eliminate cancer. This therapy is being pioneered in the clinic by CRI clinical director Jedd Wolchok, M.D., Ph.D., of Memorial Sloan Kettering Cancer Center.

Education - CRI’s new patient-oriented website,, makes immunotherapy understandable and connects patients and caregivers to clinical trials.